Scarica l'app Stockscreener
10.17
0.69%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
Is Viatris Inc. (VIA) stock resilient in recession scenariosJuly 2025 Review & Low Risk High Reward Trade Ideas - Trung tâm Dự báo KTTV quốc gia
Teva Vs. Viatris: Who Will Dominate In President Trump's America? (NASDAQ:VTRS) - Seeking Alpha
How Recent Developments Are Reshaping the Viatris Investment Story - Yahoo Finance
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - Nasdaq
How Viatris Prevents and Manages NCDs - CSRwire
Viatris completes Aculys Pharma acquisition - Seeking Alpha
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region - PR Newswire
Truist Securities initiates Viatris stock with Buy rating, sets $15 target By Investing.com - Investing.com South Africa
Truist Securities initiates Viatris stock with Buy rating, sets $15 target - Investing.com India
Night Vision Disturbances Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Ocuphire Pharma, Viatris - Barchart.com
Will Viatris Inc. stock benefit from upcoming earnings reportsMarket Performance Summary & Weekly High Conviction Ideas - newser.com
Is Viatris Inc. stock a good choice for value investorsJuly 2025 Sentiment & Community Verified Trade Alerts - newser.com
Can trapped investors hope for a rebound in Viatris Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
Pattern recognition hints at Viatris Inc. upsideJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
Nov 11 & 18: Viatris Fireside Chats at UBS and Jefferies — Live webcasts and archived access - Stock Titan
Viatris Inc. (VTRS) Stock Analysis: Exploring a 17.34% Potential Upside Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Viatris to Participate in Upcoming Investor Conferences - Sahm
Developing predictive dashboards with Viatris Inc. data2025 Market Overview & Long-Term Growth Portfolio Plans - newser.com
Viatris Inc. Stock Falls Friday, Still Outperforms Market - 富途牛牛
Does Viatris Offer Opportunity After Recent European Approval Boost? - Yahoo Finance
Kotak Alts-backed Matrix Pharma buys bulk-drugs maker - VCCircle
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Viatris’ Work To Advance Access and Public Health - CSRwire
5th Year on Forbes' World's Best Employers: Viatris Named to 2025 List After 300,000-Respondent Survey - Stock Titan
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row - The Malaysian Reserve
Viatris shares break six-session winning streak - MSN
Viatris Inc. (VTRS) Investor Outlook: Navigating a 12.15% Potential Upside Amidst Healthcare Challenges - DirectorsTalk Interviews
What analysts say about Viatris Inc stockRSI Overbought/Oversold & Small Entry Cost Trading - earlytimes.in
Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - MSN
Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK - PharmiWeb.com
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025 - BioSpace
The Importance of a Global, Resilient Supply Chain to Access - CSRwire
Relative strength of Viatris Inc. in sector analysisProduct Launch & Reliable Price Action Trade Plans - newser.com
Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com
Pharmaceutical Giant Viatris Schedules Q3 2025 Financial Results and Investor Conference Call for November 6 - Stock Titan
Will Viatris Inc. stock continue dividend increasesMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
Viatris Inc. (VTRS) Stock Analysis: Exploring a Potential 20% Upside Amid High Dividend Yield - DirectorsTalk Interviews
Quantitative breakdown of Viatris Inc. recent moveJuly 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVTRS - 2822news.com
What drives Viatris Inc stock priceBear Market Strategies & Free Unstoppable Trading Performance - earlytimes.in
What drives Viatris Inc VIA stock priceStock Buyback Updates & Build Wealth With Expert Timing Advice - earlytimes.in
What analysts say about Viatris Inc VIA stockCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Viatris Inc VIA Stock Analysis and ForecastFederal Reserve Announcements & Explosive Profit Growth - Early Times
Is Viatris Stock Underperforming the Nasdaq? - MSN
Is Viatris Stock Underperforming The Nasdaq? - Barchart.com
Viatris: Indore Plant Could Boost 2026 Numbers (NASDAQ:VTRS) - Seeking Alpha
Viatris Nixes Biogen's Extra 1-Year Protection Over MS Drug - Law360
Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection - Insider Monkey
How Viatris’ (VTRS) Removal from the FTSE All-World Index Could Affect Investor Sentiment - Sahm
Viatris Inc.(NasdaqGS: VTRS) dropped from FTSE All-World Index - MarketScreener
Viatris (VTRS): Evaluating Valuation Following FDA Nod for Generic Iron Sucrose and Pipeline Progress - Sahm
1.62%
15.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):